Stockscreener 앱 받기
2.65
2.32%
0.06
시간 외 거래:
2.65
전일 마감가:
$2.59
열려 있는:
$2.61
하루 거래량:
2.83M
Relative Volume:
0.75
시가총액:
$568.85M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-3.065
EPS:
-0.8646
순현금흐름:
$-79.23M
1주 성능:
+3.11%
1개월 성능:
+8.61%
6개월 성능:
+74.34%
1년 성능:
+16.74%
1일 변동 폭
$2.525
$2.675
1주일 범위
$2.34
$2.745
52주 변동 폭
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.65 | 677.36M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsFree Stock Chart Pattern Guide - jammulinksnews.com
What are the technical indicators suggesting about Taysha Gene Therapies Inc.Unlock powerful trading tools for investors - jammulinksnews.com
Why is Taysha Gene Therapies Inc. stock attracting strong analyst attentionBuild wealth steadily with proven strategies - jammulinksnews.com
How Taysha Gene Therapies Inc. stock performs during market volatility200 Percent Profit Outlook - Metal.it
Taysha Gene Therapies Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
Is Taysha Gene Therapies Inc. a good long term investmentLightning-fast growth - PrintWeekIndia
Can Taysha Gene Therapies Inc. stock recover from recent declineConsistently profitable trades - jammulinksnews.com
What analysts say about Taysha Gene Therapies Inc. stockFree Capital Growth Strategies - PrintWeekIndia
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
What drives Taysha Gene Therapies Inc. stock priceUnrivaled growth potential - Autocar Professional
Leigh Syndrome Market Research Report 2025-2035 | Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser
How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest
Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated at Bank of America - Defense World
Biotech Bargains: Finding Gold in the Healthcare Sell-Off - AInvest
Taysha Gene's 5.9% Surge: A Deep Dive into the Unexplained Rally - AInvest
BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating - Investing.com Canada
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News - GuruFocus
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN
Goldman Sachs Group Inc's Strategic Acquisition in Taysha Gene Therapies Inc - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies (TSHA) Gets a Buy from Wells Fargo - The Globe and Mail
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock - Nasdaq
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | - GuruFocus
Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | TSHA Stock News - GuruFocus
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):